Bruised Syros scores $130M PIPE from marquee group — while grabbing $60M cash from all-stock merger

Amber Tong

Amid a bear market that’s denting biotech share prices everywhere, raising cash sometimes takes a bit of creative thinking. Just ask Syros Pharmaceuticals.

The Cambridge …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bruised Syros scores $130M PIPE from marquee group — while grabbing $60M cash from all-stock merger

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

Ozempic makes list for next round of Medicare drug price negotiations

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

Another US biotech emerges with drug candidate from China-based Keymed

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

Bruised Sy­ros scores $130M PIPE from mar­quee group — while grab­bing $60M cash from all-stock merg­er

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Bruised Syros scores $130M PIPE from marquee group — while grabbing $60M cash from all-stock merger